Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays

被引:157
作者
Kang, HC
Kim, IJ
Park, JH
Shin, Y
Ku, JL
Jung, MS
Yoo, BC
Kim, HK
Park, JG
机构
[1] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
[2] Seoul Natl Univ, Canc Res Ctr, Seoul, South Korea
[3] Seoul Natl Univ, Inst Canc Res, Cell Biol Lab, Seoul, South Korea
关键词
D O I
10.1158/1078-0432.CCR-1025-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A major obstacle in chemotherapy is treatment failure due to anticancer drug resistance. The emergence of acquired resistance results from host factors and genetic or epigenetic changes in the cancer cells. The purpose of this study was to identify differentially expressed genes associated with acquisition of resistance in human gastric cancer cells. Experimental Design: We performed global gene expression analysis in the acquired drug-resistant gastric cancer cell lines to the commonly used drugs 5-fluorouracil, doxorubicin, and cisplatin using Affymetrix HG-U133A microarray. The gene expression patterns of 10 chemoresistant gastric cancer cell lines were compared with those of four parent cell lines using fold-change and Wilcoxon's test for data analysis. Results: We identified over 250 genes differentially expressed in 5-fluorouracil-, cisplatin-, or doxorubicin-resistant gastric cancer cell lines. Our expression analysis also identified eight multidrug resistance candidate genes that were associated with resistance to two or more of the tested chemotherapeutic agents. Among these, midkine (MDK), a heparin-binding growth factor, was overexpressed in all drug-resistant cell lines, strongly suggesting that MDK might contribute to multidrug resistance in gastric cancer cells. Conclusions: Our investigation provides comprehensive gene information associated with acquired resistance to anticancer drugs in gastric cancer cells and a basis for additional functional studies.
引用
收藏
页码:272 / 284
页数:13
相关论文
共 39 条
  • [1] Bae J M, 2001, Cancer Res Treat, V33, P367, DOI 10.4143/crt.2001.33.5.367
  • [2] Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase
    Banerjee, D
    Mayer-Kuckuk, P
    Capiaux, G
    Budak-Alpdogan, T
    Gorlick, R
    Bertino, JR
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3): : 164 - 173
  • [3] Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin
    Beyer-Sehlmeyer, G
    Hiddemann, W
    Wörmann, B
    Bertram, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (12) : 1735 - 1742
  • [4] Inhibitor of apoptosis protein survivin regulates vascular injury
    Blanc-Brude, OP
    Yu, J
    Simosa, H
    Conte, MS
    Sessa, WC
    Altieri, DC
    [J]. NATURE MEDICINE, 2002, 8 (09) : 987 - 994
  • [5] Dan S, 2002, CANCER RES, V62, P1139
  • [6] Nucleoside-mediated mitigation of 5-fluorouracil-induced toxicity in synchronized murine erythroleukemic cells
    Elstein, KH
    Mole, ML
    Setzer, RW
    Zucker, RM
    Kavlock, RJ
    Rogers, JM
    Lau, C
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 146 (01) : 29 - 39
  • [7] Mechanisms of cancer drug resistance
    Gottesman, MM
    [J]. ANNUAL REVIEW OF MEDICINE, 2002, 53 : 615 - 627
  • [8] Hippo Y, 2002, CANCER RES, V62, P233
  • [9] HOLLANDER MC, 1989, CANCER RES, V49, P1687
  • [10] Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines
    Ji, JF
    Chen, X
    Leung, SY
    Chi, JTA
    Chu, KM
    Yuen, ST
    Li, R
    Chan, ASY
    Li, JY
    Dunphy, N
    So, S
    [J]. ONCOGENE, 2002, 21 (42) : 6549 - 6556